Publications
Information about journal articles, updated at 17-05-2026, from platform CIÊNCIAVITAE.
CARACTERIZACIÓN DE PACIENTES CON CARCINOMA RENAL AVANZADO EN TRATAMIENTO CON EL INMUNOMODULADOR PROTEOLIPOSOMA DE MUY PEQUEÑA TALLA
Daisel Gómez Hernández; Iraida Caballero Aguirrechu; Oliver Rios, Liliana; Circe Mesa; Carmen Viada, Panorama. Cuba y Salud. Especial. 20. 2025. https://revpanorama.sld.cu/index.php/panorama/article/view/1832 . published Panorama. Cuba y Salud
A Bacterial and Ganglioside-based Nanoparticle Initiates Reprogramming of Macrophages and Promotes Antitumor Phenotypes
Alvarez-Arzola, Rydell; Oliver, Liliana; Messmer, Michelle M; Twum, Danielle Y F; Lee, Kelvin P; Muhitch, Jason B; Mesa, Circe; Abrams, Scott I, The Journal of Immunology. 475 - 486. 3. 212. 2024. https://doi.org/10.4049/jimmunol.2300256 . 10.4049/jimmunol.2300256 . The Journal of Immunology
Mitigating the prevalence and function of myeloid-derived suppressor cells by redirecting myeloid differentiation using a novel immune modulator
Oliver, Liliana; Alvarez, Rydell; Diaz, Raquel; Valdés, Anet; Colligan, Sean H; Nemeth, Michael J; Twum, Danielle Y F; et al, Journal for ImmunoTherapy of Cancer. 9. 10. 2022. https://doi.org/10.1136/jitc-2022-004710 . 10.1136/jitc-2022-004710 . Journal for ImmunoTherapy of Cancer
Cancer-induced systemic myeloid dysfunction: Implications for treatment and a novel nanoparticle approach for its correction
Alvarez, Rydell; Oliver, Liliana; Valdes, Anet; Mesa, Circe, Seminars in Oncology. 84 - 94. 1-2. 45. 2018. https://doi.org/10.1053/j.seminoncol.2018.05.001 . 10.1053/j.seminoncol.2018.05.001 . Seminars in Oncology
Novel Adjuvant Based on the Pore-Forming Protein Sticholysin II Encapsulated into Liposomes Effectively Enhances the Antigen-Specific CTL-Mediated Immune Response
Laborde, Rady J; Sanchez-Ferras, Oraly; Luzardo, María C; Cruz-Leal, Yoelys; Fernández, Audry; Mesa, Circe; Oliver, Liliana; et al, The Journal of Immunology. 2772 - 2784. 7. 198. 2017. https://doi.org/10.4049/jimmunol.1600310 . 10.4049/jimmunol.1600310 . The Journal of Immunology
Adjuvants and myeloid-derived suppressor cells: Enemies or allies in therapeutic cancer vaccination
Fernández, Audry; Oliver, Liliana; Alvarez, Rydell; Fernández, Luis E; Lee, Kelvin P; Mesa, Circe, Human Vaccines & Immunotherapeutics. 3251 - 3260. 11. 10. 2014. https://doi.org/10.4161/hv.29847 . 10.4161/hv.29847 . Human Vaccines & Immunotherapeutics
GM3-containing nanoparticles in immunosuppressed hosts: Effect on myeloid-derived suppressor cells
Fernández, Audry; Rios, Liliana; Rydell Alvarez Arzola; Luis E Fernández Fernández; Circe Mesa Pardillo, World Journal of Immunology. 2. 4. 2014. https://doi.org/10.5411/wji.v4.i2.98 . 10.5411/wji.v4.i2.98 . World Journal of Immunology
Very small size proteoliposomes abrogate cross-presentation of tumor antigens by myeloid-derived suppressor cells and induce their differentiation to dendritic cells
Fernández, Audry; Oliver, Liliana; Alvarez, Rydell; Hernández, Arletty; Raymond, Judith; Fernández, Luis E; Mesa, Circe, Journal for ImmunoTherapy of Cancer. 1. 2. 2014. https://doi.org/10.1186/2051-1426-2-5 . 10.1186/2051-1426-2-5 . Journal for ImmunoTherapy of Cancer
Very small size proteoliposomes derived from Neisseria meningitidis: An effective adjuvant for antigen-specific cytotoxic T lymphocyte response stimulation under leukopenic conditions
Oliver, Liliana; Fernández, Audry; Raymond, Judith; López-Requena, Alejandro; Fernández, Luis E.; Mesa, Circe, Vaccine. 2963 - 2972. 19. 30. 2012. https://doi.org/10.1016/j.vaccine.2012.02.054 . 10.1016/j.vaccine.2012.02.054 . Vaccine
Inhibition of Tumor-Induced Myeloid-Derived Suppressor Cell Function by a Nanoparticulated Adjuvant
Fernández, Audry; Mesa, Circe; Marigo, Ilaria; Dolcetti, Luigi; Clavell, Marilyn; Oliver, Liliana; Fernández, Luis E; Bronte, Vincenzo, The Journal of Immunology. 264 - 274. 1. 186. 2011. https://doi.org/10.4049/jimmunol.1001465 . 10.4049/jimmunol.1001465 . The Journal of Immunology
5 10 out of 10 Publications
All projects
Information of exclusive responsibility of the researcher 17-05-2026 , from platform CIÊNCIAVITAE.
2024/08/01 -
CInTech: Technological Hub for Innovation, Translation and Industrialization of Complex Injectable Drugs
C644865576-00000005
Post-doc Fellow
Universidade de Coimbra Centro de Inovação em Biomedicina e Biotecnologia
2023/04/01 - 2024/05/31
Clinical trial: Phase I–II dose-escalation and cohort-expansion study of synthetic VSSP in patients with metastatic renal carcinoma.
0000000
Researcher
Centro de Inmunología Molecular; Hospital Clíinico Quirúrgico Hermanos Ameijeiras
2017 - 2018
VSSP-mediated modulation of macrophage phenotype and function in tumor-bearing animals
P-1-04150
Researcher
Centro de Inmunología Molecular; Roswell Park Comprehensive Cancer Center
2017/09/13 - 2022/09/13
Very Small Size Particles (VSSP)-Mediated Reprogramming of Aberrant Myelopoiesis toward Functional Antigen-Presenting Cells
P-1-04150
Principal investigator
Centro de Inmunología Molecular; Roswell Park Comprehensive Cancer Center
2016 - 2018
Clinical trial: Windows of opportunity: Effect of VSSP on myeloid-derived suppressor cells (MDSCs) in patients with stage II breast cancer.
00
Researcher
Centro de Inmunología Molecular; Instituto Nacional de Oncología y Radiobiología
2012/11/12 - 2013/09/03
Relation of Myeloid derived suppressor cells (MDSC) and Type 1 Diabetes
0000000
Principal investigator
Lunds universitet Clinical Research Centre
2010 - 2014
Clinical trial: VSSP as an immunopotentiator for the treatment of patients with metastatic renal cell carcinoma (mRCC): first clinical approaches. Protocol number: PL 009
PL-009
Researcher
Centro de Inmunología Molecular; Hospital Docente Clínico Quirúrgico Joaquín Albarrán
5 7 out of 7 projects
We use cookies to improve your visit to our website.
